Governance Neutral

2026-11-06 11:48

- Aptus Pharma Ltd has intimated that a Board Meeting is scheduled for 12th November 2026. - The purpose of the meeting is to consider and approve the allotment of equity shares on a preferential basis. - The preferential allotment follows shareholder approval at the AGM on 14th September 2026 and BSE in-principle approval on 30th October 2026.

Business Update Positive

2026-10-30 19:40

- Aptus Pharma Ltd has received in-principle approval from BSE Limited on October 30, 2026, for the proposed preferential issue of equity shares. - The preferential issue was earlier approved by shareholders at the Annual General Meeting held on September 14, 2026.

Business Update Positive

2026-10-29 19:39

Management Guidance & Outlook - Management refrained from providing specific forward-looking numbers or guidance for topline, EBITDA, or PAT margins for the next 2-3 years. - Targeting a pan-India presence with product availability in every medical store by 2029. - Aiming to achieve 46% geographic coverage across India by March 2027. Capex & Manufacturing Strategy - Planning initial manufacturing expansion with a capex of approximately Rs. 35 crore (partially funded via preferential issue of Rs. 25 crore), targeted for completion by March 2028. - The upcoming manufacturing plant will be dedicated to self-consumption (to manufacture around 20% of the product portfolio) and exports to Rest of the World (ROW) countries. Growth Drivers & Business Mix - Core business model focuses on prescription generation, supported by a diverse portfolio of over 300 formulations across acute, chronic, wellness, and OTC segments. - Revenue mix stands at ~44% acute therapy, ~20% chronic/semi-chronic, ~20% wellness/OTC, and ~16% services. - Strong distribution network comprising over 250 distributors/sub-distributors and an on-roll frontline sales team of 142 medical representatives.

Business Update Neutral

2026-10-26 19:44

- Aptus Pharma Ltd has uploaded the audio recording of the earnings call held on October 26, 2026. - The call was conducted to discuss the financial results for the half year ended September 30, 2026. - The recording is accessible on the company's official website.

Business Update Neutral

2026-10-23 17:32

- Investor presentation released for the half year ended September 30, 2026. - Portfolio spans 300+ formulations across chronic, acute, and wellness segments. - Network encompasses 45,000+ retail points and 250+ distributors. - Targeting 46% geographic coverage across India by March 2027.

Business Update Neutral

2026-10-21 18:07

Concall Schedule Concall Date: 26 October 2026 Concall Time: 05:00 PM IST

Financials Positive

2026-10-20 19:32

H1 FY27 Standalone Revenue ₹48.92Cr vs ₹18.38Cr (▲166% YoY) EBITDA ₹7.91Cr vs ₹2.95Cr (▲168% YoY) PAT ₹5.08Cr vs ₹1.75Cr (▲191% YoY) EBITDA Margin 16.2% vs 16.1% (▲10bps)

Financials Positive

2026-10-20 19:01

H1 FY27 Standalone Revenue ₹48.92Cr vs ₹18.38Cr (▲166.2% YoY) EBITDA ₹7.89Cr vs ₹2.95Cr (▲167.5% YoY) PAT ₹5.08Cr vs ₹1.75Cr (▲190.6% YoY) EBITDA Margin 16.1% vs 16.1% (▲6bps)

Routine Neutral

2026-09-28 12:18

- Trading window for dealing in securities of Aptus Pharma Ltd will remain closed from October 1, 2026. - Closure continues until 48 hours after the declaration of financial results for the half year ended September 30, 2026.

Business Update Neutral

2026-09-17 14:38

- Investor Meeting Schedule - Meeting Date: September 25, 2026 - Meeting Time: 3:00 PM - 4:00 PM - Event: Arihant Capital: Bharat Connect Conference - Rising Stars (Virtual Group Meeting)

Governance Positive

2026-09-14 20:27

- APTUS PHARMA LIMITED announced the e-voting results of its 16th Annual General Meeting held on September 14, 2026. - All three resolutions, including adoption of financial statements for FY ended March 31, 2026, re-appointment of a director, and approval of preferential allotment of equity shares, were passed with 100% votes in favour.

Governance Neutral

2026-09-14 19:41

- The 16th Annual General Meeting (AGM) of Aptus Pharma Limited was held on September 14, 2026. - Shareholders adopted the Audited Financial Statements for the financial year ended March 31, 2026. - Mr. Chetan Shantilal Lalseta was re-appointed as a Director. - Approval was granted for a Preferential Allotment of Equity shares.

Business Update Neutral

2026-09-12 13:34

- Investor Meeting Schedule - Meeting Date: September 18, 2026 - Meeting Time: 4:00 - 6:00 pm

Business Update Positive

2026-08-24 13:36

- Aptus Pharma announces next growth phase: focus on manufacturing, Pan-India expansion, and global markets. - Board approved ₹44.88 crore preferential issue to fund capital expenditure (₹25 Cr), working capital (₹10 Cr), and general corporate purposes including debt reduction. - Aims for 20% in-house manufacturing.

Routine Neutral

2026-08-21 19:48

New Filing detected. See link for details.

Governance Positive

2026-08-17 18:07

- Board meeting held on August 17, 2026, approved a preferential issue of 16,02,870 equity shares. - Shares to be issued at ₹280 per equity share, raising a total of ₹44.88 Crores. - The Board also approved the convening of the 16th Annual General Meeting on September 14, 2026.

Governance Neutral

2026-08-12 17:57

- Board Meeting of Aptus Pharma Limited is scheduled for Monday, August 17, 2026, at 4:00 p.m. - Agenda includes taking on record valuation reports and determining the issue price for a preferential issue of 16,10,100 equity shares. - Also, to approve the convening of the 16th Annual General Meeting (AGM) on Monday, September 14, 2026. - Trading window closed from August 12, 2026, until 48 hours after the Board Meeting.

Governance Neutral

2026-08-10 14:41

- Aptus Pharma Limited issued a clarification for typographical errors in the Outcome of the Board Meeting dated August 08, 2026. - Errors concerned the meeting venue description and an annexure title. - The company confirmed these errors were purely typographical and do not change the substance or outcome of the Board's decisions.

Governance Positive

2026-08-08 17:30

- Board of Directors meeting held on August 08, 2026. - Approved preferential issue of 16,10,100 equity shares of ₹10 face value each, subject to shareholder approval. - Fixed the Annual General Meeting (AGM) for Monday, September 14, 2026. - The 'Relevant Date' for determining the minimum price for the Preferential Allotment is Friday, August 14, 2026. - Appointed CS Amrish N. Gandhi FCS as Registered Valuer for fixing the price of equity shares.

Governance Neutral

2026-08-05 18:47

- Board Meeting scheduled for August 8, 2026, at 4:00 p.m. to consider raising funds through preferential allotment. - Trading window closed from August 5, 2026, until 48 hours after the Board Meeting outcome.

Business Update Neutral

2026-06-27 13:43

- CARE Ratings Limited assigned a 'CARE BB; Stable' Issuer rating to Aptus Pharma Limited. - The rating reflects modest scale and stretched liquidity (weaknesses), balanced by experienced promoters and healthy profitability (strengths).

Business Update Positive

2026-06-12 17:47

- Board of Directors approved raising funds up to ₹51 Crores for business expansion. Funds will be raised through Preferential Allotment (₹35 Cr), Debt Finance (₹10 Cr), and Internal Accruals (₹6 Cr). Final details are subject to further approvals.

Routine Neutral

2026-06-09 18:43

New Filing detected. See link for details.

Routine Neutral

2026-06-09 18:35

New Filing detected. See link for details.

Business Update Positive

2026-05-22 18:18

Aptus Pharma Limited has undertaken a strategic brand-building initiative by taking over the Baby Care Room at Rajkot Hirasar Airport. This is to promote its upcoming baby care and OTC product portfolio, enhance brand visibility among travellers and families, and strengthen awareness of its expanding healthcare range. The initiative aims to strengthen customer trust, improve market reach, and establish a stronger presence in the OTC and baby care segment.

Ownership Neutral

2026-05-14 08:48

Kripaliben Mayank Thakker, identified as part of the Promoter Group of Aptus Pharma Limited, disclosed the acquisition of 18,000 equity shares (0.26%) of the company on May 11, 2026. This transaction was an off-market inter-se transfer among the Promoter Group. Her shareholding increased from 5,75,000 shares (8.38%) before the acquisition to 5,93,000 shares (8.64%) after the acquisition.

Ownership Positive

2026-05-14 08:45

Kunjal Piyushbhai Unadkat, a promoter of Aptus Pharma Limited, acquired 18,000 equity shares (0.26%) of the company on May 11, 2026. This off-market inter-se transfer within the promoter group increased his total holding from 8.38% to 8.64% of the total share capital.

Ownership Neutral

2026-05-14 08:40

Riddhish Natwarlal Tanna, part of the promoter group of Aptus Pharma Limited, disclosed an acquisition of 18,000 equity shares (0.26%) of the company on May 11, 2026. This was an off-market inter-se transfer within the promoter group, increasing the total promoter group holding from 8.38% (5,75,000 shares) to 8.64% (5,93,000 shares).

Ownership Positive

2026-05-14 08:36

Milly Chetan Lalseta, part of the Promoter/Promoter Group, acquired 18,000 equity shares of Aptus Pharma Limited via an off-market inter-se transfer on May 11, 2026. This acquisition increased the promoter group's total shareholding from 5,75,000 shares (8.38%) to 5,93,000 shares (8.64%). The disclosure was made under Regulation 29(1)/29(2) of SEBI (SAST) Regulations, 2011.

Ownership Neutral

2026-05-14 08:31

Gaurang Rameshchandra Thakker, a promoter of Aptus Pharma Limited, acquired 18,000 equity shares of the company on May 11, 2026. This off-market inter-se transfer increased his holding from 5,75,000 shares (8.38%) to 5,93,000 shares (8.64%) of the total voting capital. The acquisition represents a 0.26% increase in his stake.

Ownership Neutral

2026-05-14 08:25

Mr. Chatrabhuj Vallabhbhai Butani, a promoter of Aptus Pharma Limited, disclosed an off-market inter-se transfer/sale of 1,24,000 equity shares (1.81%) on May 11, 2026. His holding reduced from 2,25,000 shares (3.28%) to 1,01,000 shares (1.47%) as a result of this transaction within the promoter group.

Ownership Neutral

2026-05-13 17:44

Ghanshyam Vinubhai Pansuriya, part of the Promoter Group of Aptus Pharma Limited, disclosed the acquisition of 14,000 equity shares through an off-market inter-se transfer on May 11, 2026. This increased the promoter's holding from 3,50,000 shares (5.10%) to 3,64,000 shares (5.31%) in the company.

Ownership Positive

2026-05-13 17:44

Tejash Maheshchandra Hathi, a promoter of Aptus Pharma Limited, acquired 10,000 equity shares off-market on May 11, 2026. This acquisition increased the promoter's holding from 7,75,000 shares (11.30% of total voting capital) to 7,85,000 shares (11.44% of total voting capital). The disclosure was made under Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011.

Ownership Positive

2026-05-13 17:39

Kapilbhai Hasmukhbhai Chandarana, belonging to the Promoter Group of Aptus Pharma Limited, acquired 10,000 equity shares off-market on May 11, 2026. This acquisition increased the promoter group's holding from 7,75,000 shares (11.30%) to 7,85,000 shares (11.44%) of the company's total share capital.

APPL

Aptus Pharma Ltd

Price Chart

Filing History

Unlock Full History